Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Trastuzumab in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description
Herceptin (trastuzumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab.